TET2 and mature T-cell and NK-cell non-Hodgkin lymphoma: We present a case of a patient with PTCL-NOS who progressed despite multiple treatment regimens, including both traditional and novel therapeutic agents, and finally achieved good results with azacytidine, selected based on a TET2 mutation.